☆ 4.4 Letter

Response to Feemster KA et al. letter to the editor on Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan

EXPERT REVIEW OF VACCINES (2022)

Get Full Text
Add to Collection

Journal

EXPERT REVIEW OF VACCINES
Volume 21, Issue 5, Pages 591-592

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/14760584.2022.2036129

Keywords

-

Categories

Immunology

Funding

  1. Pfizer Japan Inc., Tokyo, Japan

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.